Cubist Systematic Strategies, LLC Cti Biopharma Corp Transaction History

Cubist Systematic Strategies, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$4.45 - $6.17 $561,420 - $778,419	-126,162 Reduced 47.8%	137,794 $828,000
Q3 2022 Nov 14, 2022	BUY	$5.36 - $7.43 $1.07 Million - $1.49 Million	200,133 Added 313.58%	263,956 $1.54 Million
Q2 2022 Aug 15, 2022	SELL	$3.55 - $6.27 $1.66 Million - $2.93 Million	-467,777 Reduced 87.99%	63,823 $381,000
Q1 2022 May 16, 2022	BUY	$1.9 - $5.23 $1.01 Million - $2.78 Million	531,600 New	531,600 $2.48 Million
Q4 2021 Feb 14, 2022	SELL	$1.44 - $2.86 $26,212 - $52,060	-18,203 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$2.25 - $3.18 $74,439 - $105,207	-33,084 Reduced 64.51%	18,203 $54,000
Q2 2021 Aug 16, 2021	BUY	$2.16 - $2.62 $56,734 - $68,816	26,266 Added 104.98%	51,287 $128,000
Q1 2021 May 17, 2021	BUY	$2.68 - $3.8 $67,056 - $95,079	25,021 New	25,021 $73,000

Ticker CTIC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 114,385,000
Market Cap $1.04B
Description
CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States. It offers VONJO (pacritinib), an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R for the treatment of adult patients w...

Get notified when there are updates to the investment portfolio of Cubist Systematic Strategies, LLC, based on Form 13F filings with the SEC.

Stay updated on Cubist Systematic Strategies, LLC with notifications on news.